P394: Preoperative serum vedolizumab levels do not predict postoperative outcomes in inflammatory bowel disease (IBD)ECCO '18 Vienna
2018
P395: Dermatological reactions associated with anti–TNF therapy in inflammatory bowel disease- an 12 year experienceECCO '18 Vienna
2018
P396: Pharmacokinetics, immunogenicity and clinical outcomes of golimumab from the PURSUIT PEDS ulcerative colitis study long-term (through week 126) extensionECCO '18 Vienna
2018
P397: Effectiveness of vedolizumab (VDZ) for the induction of remission in inflammatory bowel disease (IBD): Results from the Spanish Eneida RegistryECCO '18 Vienna
2018
P398: Cannabis induces clinical and endoscopic improvement in moderately active ulcerative colitis (UC)ECCO '18 Vienna
2018
P399: Vedolizumab therapy results in reduced hospitalisation and steroid use over 1-year: Results from the Scottish vedolizumab consortiumECCO '18 Vienna
2018
P401: Reduction of dosing intervals is the preferable dose optimisation strategy for infliximab to suppress formation of anti-drug antibodiesECCO '18 Vienna
2018
P402: Interstitial and granulomatous lung disease in inflammatory bowel disease patientsECCO '18 Vienna
2018
P404: Development of anti-drug antibodies among those treated with adalimumab and ABP 501 and its impact on serum drug concentration in randomised controlled studiesECCO '18 Vienna
2018
P405: 5-ASA prescription trends over time in inflammatory bowel disease 1996 to 2015–A UK population-based studyECCO '18 Vienna
2018
P406: Malnutrition during hospitalisation for acute severe IBD is associated with increased risk of relapseECCO '18 Vienna
2018
P409: Long-term safety and effectiveness of adalimumab in 462 patients with intestinal Behçet’s disease: Results from a real-world observational studyECCO '18 Vienna
2018
P411: Benefits of implementing a rapid access clinic in a high-volume inflammatory bowel disease centre: Accessibility, resource utilisation and outcomesECCO '18 Vienna
2018